VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-16.23%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.57B
AUM Growth
+$1.57B
(-25%)
Cap. Flow
-$35.2M
Cap. Flow
% of AUM
-2.24%
Top 10 Holdings %
Top 10 Hldgs %
64.59%
Holding
44
New
6
Increased
6
Reduced
3
Closed
9
Top Buys
| 1 |
Erasca
ERAS
|
$38.3M |
| 2 |
Cullinan Oncology
CGEM
|
$24.1M |
| 3 |
Zura Bio
ZURA
|
$21.1M |
| 4 |
Spyre Therapeutics
SYRE
|
$12.1M |
| 5 |
PCSC
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
|
$7.55M |
Top Sells
| 1 |
HilleVax
HLVX
|
$34.5M |
| 2 |
Merus
MRUS
|
$31.2M |
| 3 |
Celcuity
CELC
|
$21M |
| 4 |
Immatics
IMTX
|
$18.4M |
| 5 |
Lyra Therapeutics
LYRA
|
$16M |
Sector Composition
| 1 | Healthcare | 99.52% |
| 2 | Financials | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arvinas
ARVN
$568M
| $16.7M | 1.06% | 627,788 | – | – |
|
27
Aquestive Therapeutics
AQST
$456M
| $14.4M | 0.92% | 5,555,555 | – | – |
|
28
Century Therapeutics
IPSC
$42.5M
| $13.7M | 0.88% | 5,389,259 +1,984,126 | +58% | +$5.06M |
|
29
Cabaletta Bio
CABA
$133M
| $11.7M | 0.75% | 1,563,952 | – | – |
|
30
Trevi Therapeutics
TRVI
$883M
| $10.2M | 0.65% | 3,422,637 -38 | -0% | -$113 |
|
31
Adverum Biotechnologies
ADVM
$64.6M
| $10.1M | 0.64% | 1,467,048 -89,371 | -6% | -$613K |
|
|
PCSC
32
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.55M | 0.48% | +750,000 | New | +$7.55M |
|
33
Tenaya Therapeutics
TNYA
$184M
| $4.82M | 0.31% | 1,555,556 | – | – |
|
|
ORKA
34
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $3.32M | 0.21% | +866,375 | New | +$3.32M |
|
35
CASI Pharmaceuticals
CASI
$35.8M
| $614K | 0.04% | +111,686 | New | +$614K |
|
|
36
Celcuity
CELC
$2.17B
| – | – | -970,000 | Closed | -$21M |
|
37
CG Oncology
CGON
$2.04B
| – | – | -350,000 | Closed | -$15.4M |
|
38
EyePoint Pharmaceuticals
EYPT
$797M
| – | – | -250,000 | Closed | -$5.17M |
|
|
39
HilleVax
HLVX
$105M
| – | – | -2,075,000 | Closed | -$34.5M |
|
|
40
Immatics
IMTX
$619M
| – | – | -1,750,000 | Closed | -$18.4M |
|
|
41
Lyra Therapeutics
LYRA
$11.5M
| – | – | -2,576,093 | Closed | -$16M |
|
42
Mineralys Therapeutics
MLYS
$1.03B
| – | – | -555,554 | Closed | -$7.17M |
|
43
Olema Pharmaceuticals
OLMA
$375M
| – | – | -77,042 | Closed | -$872K |
|
|
SLRN
44
DELISTED
ACELYRIN
SLRN
| – | – | -937,113 | Closed | -$6.33M |
|